A Phase IIa, Randomized, Double-Blind Placebo-Controlled, Dose Comparison, Multi-Centre Adaptive Design Clinical Trial to Evaluate The Immune Signature of The Treatment with The Imotopeā„¢ IMCY-0098 and its effect on the Preservation of Beta-Cell Function in Adult Patients with A Recent Onset Type 1 Diabetes


Awarded By

Total Award Amount

  • 175000.00
  • Direct Costs

  • 134615.00
  • Sponsor Award Id

  • Contributor

  • Amy Warriner   Investigator  
  • Fernando Ovalle   Principal Investigator